Britain and America have signed a significant bilateral deal that will guarantee zero duties on UK drug exports being sold in the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the public health system. This commitment ensures that duties on these crucial products will be held at zero for a timeframe of 36 months.
This deal is in response to previous threats to significantly raise duties on branded pharmaceutical imports, with potential rates discussed up to 100%.
"This deal with the UK reinforces the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. drug exports," a release noted.
Economic Significance
Drugs are one of the Britain's biggest goods shipped to the America, which is easily the biggest market for major UK drugmakers.
Trade data reveal that in the 12 months leading up to September, the UK shipped medicines worth over eleven billion pounds to the US. This figure represented 17.4% of British export trade in that timeframe.
"This guarantee protects employment, increases investment and facilitates the UK to establish itself as a global hub for life sciences," a government official remarked.
Specific UK Commitments
The pact includes several key pledges from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must pay back to the NHS to control costs will be limited at 15%. Last year, rebates exceeded 20%.
Recent Tensions
The pact follows a long-running tension between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by claims that US consumers were paying a premium for the equivalent treatments than people in the Britain and the EU.
Recently, several significant drug company projects in the UK have been delayed or scrapped, while substantial funding commitments have been directed toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its total funding over the last ten years.
